Masimo (NASDAQ:MASI) Updates FY22 Earnings Guidance

Masimo (NASDAQ:MASI) issued an update on its FY22 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $4.34 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.35. The company issued revenue guidance of $1.35 billion, compared to the consensus revenue estimate of $1.35 billion.Masimo also updated its FY21 guidance to above $3.88 EPS.

MASI stock opened at $254.38 on Tuesday. The business has a fifty day moving average of $285.06 and a 200-day moving average of $276.51. The company has a market cap of $14.05 billion, a P/E ratio of 63.44 and a beta of 0.73. Masimo has a twelve month low of $205.10 and a twelve month high of $305.21.

Masimo (NASDAQ:MASI) last released its quarterly earnings data on Monday, October 25th. The medical equipment provider reported $0.94 EPS for the quarter, beating analysts’ consensus estimates of $0.91 by $0.03. The business had revenue of $307.40 million during the quarter, compared to the consensus estimate of $295.79 million. Masimo had a return on equity of 15.56% and a net margin of 19.23%. The firm’s revenue was up 10.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.80 earnings per share. On average, analysts predict that Masimo will post 3.88 EPS for the current year.

A number of research firms recently commented on MASI. Raymond James began coverage on Masimo in a report on Tuesday, October 12th. They issued a market perform rating for the company. Piper Sandler increased their price target on Masimo from $320.00 to $330.00 and gave the stock an overweight rating in a report on Monday, November 15th. Finally, Zacks Investment Research upgraded Masimo from a hold rating to a buy rating and set a $298.00 price target for the company in a report on Monday, September 27th.

In other Masimo news, CEO Joe E. Kiani sold 3,429 shares of the company’s stock in a transaction that occurred on Monday, November 1st. The stock was sold at an average price of $290.08, for a total value of $994,684.32. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Joe E. Kiani sold 18,967 shares of the company’s stock in a transaction that occurred on Friday, October 29th. The shares were sold at an average price of $290.97, for a total value of $5,518,827.99. The disclosure for this sale can be found here. Insiders sold 136,389 shares of company stock valued at $40,425,338 over the last 90 days. Corporate insiders own 9.10% of the company’s stock.

Masimo Company Profile

Masimo Corp. is a medical technology company, which develops, manufactures and markets non invasive patient monitoring technologies, medical devices and sensors. Its products include continuous monitors, patient-worn monitors, hospital automation connectivity, capnography & gas, data download & analytics and sensors & accessories.

Featured Story: How to Invest in Marijuana Stocks

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.